Onderzoeker
Jurgen Corthals
- Onderzoeksexpertise:
The main goal of my research activities at the laboratory of Molecular and Cellular Therapy (LMCT) is to develop an integrated partnership between immunotherapy and conventional cancer treatment. Innovative immuno-modulatory and immuno-therapeutic strategies are being tested in preclinical models and translated towards clinical applications in phase I/II trials.
Research topics – projects
- Messenger RNA based immunotherapy of melanoma
- Multitargeted therapy: development of novel therapeutic combination for augmenting the potency of cancer vaccines.
- Study of the tumor microenvironment to develop predictive in silico models of personalized immunotherapy.
- Characterization of spontaneous and vaccine-induced immune responses against melanoma, and analysis of their influence on the clinical course of the patients.
- Enhancing tumor immunity by intranodal injection of mRNA encoding tumor antigens and activation stimuli
- Inhibitory mechanisms exerted by melanoma cells and their environment
- Dendritic cell therapy in cancer patients
Clinical trials
- A phase II study of TriMix-DC in combo with Ipilimumab in Patients with unresectable Stage III or IV melanoma
- A Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases
- Trefwoorden:Geneeskunde
- Gebruikers van onderzoeksexpertise:
The main goal of my research activities at the laboratory of Molecular and Cellular Therapy (LMCT) is to develop an integrated partnership between immunotherapy and conventional cancer treatment. Innovative immuno-modulatory and immuno-therapeutic strategies are being tested in preclinical models and translated towards clinical applications in phase I/II trials.
Research topics – projects
- Messenger RNA based immunotherapy of melanoma
- Multitargeted therapy: development of novel therapeutic combination for augmenting the potency of cancer vaccines.
- Study of the tumor microenvironment to develop predictive in silico models of personalized immunotherapy.
- Characterization of spontaneous and vaccine-induced immune responses against melanoma, and analysis of their influence on the clinical course of the patients.
- Enhancing tumor immunity by intranodal injection of mRNA encoding tumor antigens and activation stimuli
- Inhibitory mechanisms exerted by melanoma cells and their environment
- Dendritic cell therapy in cancer patients
Clinical trials
- A phase II study of TriMix-DC in combo with Ipilimumab in Patients with unresectable Stage III or IV melanoma
- A Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases